Procedure proves safe, precise


Lenticule extraction found effective for patients with myopia and myopic astigmatism

His statement was based on analysis of outcomes in a series of 94 eyes followed for up to 1 year after undergoing the proprietary refractive procedure (ReLEx, Carl Zeiss Meditec) that is based on tissue removal rather than ablation.

"There is only a small learning curve for performing this procedure, it is very comfortable for patients, complications occur rarely and have been nonvision threatening, and only a single instrument, a femtosecond laser (VisuMax) is needed for the refractive procedure," said Dr Graue-HernÁndez, head, Department of Cornea and Refractive Surgery, Institute of Ophthalmology, Conde de Valenciana, Mexico City, Mexico.

Patients were eligible for inclusion in the study if they had up to –10 D of myopia and up to –5 D cylinder, had demonstrated refractive stability for at least 1 year, and would otherwise be considered candidates for LASIK based on their pachymetry, topography and estimated residual stromal bed thickness.

The patients had a mean age of 27 years (range 18 to 46 years), manifest refractive spher­ical equivalent (MRSE) of –4.34 D (range to –8 D), mean sphere of –3.26 D (range to –6.75 D), and mean cylinder of –1.5 D (range to –5 D). Twelve eyes were eliminated from the efficacy analysis because the lenticule could not be lifted; these patients underwent femto-LASIK instead. All of the remaining 82 eyes were seen at 1 day and 1 week after surgery, 74 eyes were seen for follow-up at 1 month, 49 eyes at 6 months and 22 eyes completed 1 year of follow-up.

Positive results

The analysis of refractive results showed achieved mean MRSE at 1 week was close to plano (0.17 ± 0.74 D). Over time, there was a trend toward a myopic shift, and mean MRSE at 1 year was –0.27 ± 0.82 D. Only 4% of eyes followed from 3 to 12 months, however, had a refractive change >0.5 D.

At 1 month, achieved MRSE was within 1 D of attempted in 85% of eyes and within 0.5 D in 70%. The results for predictability of the cylinder correction were similar. Distance UCVA was 20/40 or better in 99% of eyes at 1 month, although only 46% saw 20/20 or better, Dr Graue-HernÁndez noted.

Safety was good, and no eyes lost more than 1 line of best-corrected visual acuity (BCVA), while 80% remained the same and only 11% gained 1 line.

Aside from the inability to lift the lenticule, complications encountered intraoperatively included two cases (2.1%) in which the lenticule remained on the flap - which Dr Graue-HernÁndez characterized as a learning curve issue - and one case where the lenticule was broken at the edge. There were no cases of suction loss or epithelium breaches during the procedure, he noted.

Dry eye (11.7%) was the most common complication during postoperative follow-up. Striae developed in two eyes (2.1%), mild haze in one eye (1.1%), and stromal opacities in four eyes (4.2%).

"The opacities could take a very long time to fade away, but they did not seem to bother the patient or lead to complaints," Dr Graue-HernÁndez said.

In addition, the treatment was decentred in one case and resulted in high mixed astigmatism, he noted. The involved patient was the only one in the series that had a 1-line loss of BCVA.

Special contributor

Dr Enrique Graue-HernÁndez, MD, is head of the Department of Cornea and Refractive Surgery, Institute of Ophthalmology, Conde de Valenciana, Mexico City, Mexico. He may be reached by E-mail:

Dr Graue-HernÁndez has indicated no financial interests in the subject matter.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.